

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#20/B BD 5-8-03 (NE)

ennos portes portes

In re application of

C nfirmation No. 7242

Minoru FUJIMORI et al.

Docket No. 2001 0206A

Serial No. 09/816,391

Group Art Unit 1635

Filed March 26, 2001

Examiner B. Whiteman

ANAEROBIC BACTERIUM AS A DRUG FOR CANCER GENE THERAPY

RESPONSE UNDER 37. CFR 1.116

Life Proceeding

77 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35 16 35

AMENDMENT AFTER FINAL

RECEIVED

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAY 0 7 2003

Sir:

TECH CENTER 1600/2900

Responsive to the Office Action issued January 2, 2002, the time for responding thereto being extended for one month in accordance with a petition for extension submitted concurrently herewith, please amend the above-identified application as follows:

IN THE CLAIMS

Please amend the claims as follows:

14. (Twice Amended) A method for expressing a gene coding for a protein having an antitumor activity in tissue tumors specifically, which comprises use of a bacterium selected from the group consisting of Bifidobacterium adolescentis, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium pseudolongum, Bifidobacterium thermophirum, Bifidobacterium breve, Bifidobacterium infantis, wherein said bacterium is transformed with a recombinant DNA, said DNA is used as a gene delivery vector, and said DNA delivered specifically to tumor tissues under anaerobic conditions is expressed in the tumor tissues.